Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Boule Diagnostics: Analyst - ABG

Boule Diagnostics

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Q4'23 results due 6 February
Instrument sales to drive growth in Q4e
27-33% below historical NTM P/E and NTM EV/EBITDA


Q4'23e expectations

We expect Boule Diagnostics to report +2.4% organic sales growth and an EBIT margin of 8.2% in Q4'23e, up from 6.7% in Q4'22. Sales growth in Q4 is expected to come from instrument sales, with sales of consumables facing tough comps in Q4'23 ahead of an expected decline in Q4'23. Given the expected sales mix, i.e. tilted more towards instruments in Q4 and thus holding back the gross margin, we forecast an improved EBIT margin in Q4 on good cost control.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team